MA41197B1 - Traitement de le pemphigus - Google Patents

Traitement de le pemphigus

Info

Publication number
MA41197B1
MA41197B1 MA41197A MA41197A MA41197B1 MA 41197 B1 MA41197 B1 MA 41197B1 MA 41197 A MA41197 A MA 41197A MA 41197 A MA41197 A MA 41197A MA 41197 B1 MA41197 B1 MA 41197B1
Authority
MA
Morocco
Prior art keywords
pemphigus
corticosteroids
therapy
relates
present
Prior art date
Application number
MA41197A
Other languages
English (en)
Inventor
Steven Gourlay
Original Assignee
Principia Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Principia Biopharma Inc filed Critical Principia Biopharma Inc
Publication of MA41197B1 publication Critical patent/MA41197B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des procédés de traitement, avec un inhibiteur de btk, d'une maladie bulleuse, en particulier du pemphigus vulgaire ou du pemphigus foliacé chez un mammifère, l'utilisation d'un inhibiteur de btk en tant que thérapie de remplacement d'une thérapie par corticoïdes pour les maladies pouvant être traitées avec des corticoïdes, telles qu'une maladie auto-immune ou une maladie inflammatoire et en particulier lorsque des corticoïdes sont utilisés comme thérapie de première ou de seconde ligne. La présente invention concerne également des formulations pharmaceutiques comprenant ces inhibiteurs de btk.
MA41197A 2014-12-18 2015-12-18 Traitement de le pemphigus MA41197B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462093891P 2014-12-18 2014-12-18
PCT/US2015/066868 WO2016100914A1 (fr) 2014-12-18 2015-12-18 Traitement du pemphigus

Publications (1)

Publication Number Publication Date
MA41197B1 true MA41197B1 (fr) 2021-01-29

Family

ID=55080225

Family Applications (1)

Application Number Title Priority Date Filing Date
MA41197A MA41197B1 (fr) 2014-12-18 2015-12-18 Traitement de le pemphigus

Country Status (14)

Country Link
US (2) US10485797B2 (fr)
EP (1) EP3233103B1 (fr)
CN (1) CN107257686B (fr)
AU (2) AU2015364335B2 (fr)
CA (1) CA2970723C (fr)
EA (1) EA036269B1 (fr)
ES (1) ES2843323T3 (fr)
IL (1) IL252839B (fr)
MA (1) MA41197B1 (fr)
MX (1) MX381283B (fr)
PL (1) PL3233103T3 (fr)
PT (1) PT3233103T (fr)
SG (1) SG11201704808VA (fr)
WO (1) WO2016100914A1 (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2892900T1 (en) 2012-09-10 2018-01-31 Principia Biopharma Inc. Pyrazolopyrimidine compounds as kinase inhibitors
CA2902686C (fr) 2013-04-25 2017-01-24 Beigene, Ltd. Composes heterocycliques fusionnes en tant qu'inhibiteurs de proteine kinase
CN112552401B (zh) 2013-09-13 2023-08-25 广州百济神州生物制药有限公司 抗pd1抗体及其作为治疗剂与诊断剂的用途
CN112353806A (zh) 2014-02-21 2021-02-12 普林斯匹亚生物制药公司 Btk抑制剂的盐和固体形式
CN106604742B (zh) 2014-07-03 2019-01-11 百济神州有限公司 抗pd-l1抗体及其作为治疗剂及诊断剂的用途
SG11201704808VA (en) 2014-12-18 2017-07-28 Principia Biopharma Inc Treatment of pemphigus
WO2016210165A1 (fr) 2015-06-24 2016-12-29 Principia Biopharma Inc. Inhibiteurs de la tyrosine kinase
CN115054586B (zh) 2016-06-29 2024-08-02 普林斯匹亚生物制药公司 改性的释放制剂
US10864203B2 (en) 2016-07-05 2020-12-15 Beigene, Ltd. Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer
WO2018033853A2 (fr) * 2016-08-16 2018-02-22 Beigene, Ltd. Forme cristalline de (s)-7-(1-acryloylpipéridin-4-yl)-2-(4-phénoxyphényle)-4,5,6,7-tétra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, sa préparation et ses utilisations
WO2018033135A1 (fr) * 2016-08-19 2018-02-22 Beigene, Ltd. Utilisation d'une combinaison comprenant un inhibiteur de btk pour le traitement de cancers
WO2018109050A1 (fr) * 2016-12-15 2018-06-21 F. Hoffmann-La Roche Ag Procédé de préparation d'inhibiteurs de btk
CN108329274B (zh) * 2017-01-13 2021-09-03 正大天晴药业集团股份有限公司 布鲁顿酪氨酸激酶抑制剂
US11555038B2 (en) 2017-01-25 2023-01-17 Beigene, Ltd. Crystalline forms of (S)-7-(1-(but-2-ynoyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
CN108727404B (zh) * 2017-04-14 2020-05-12 中国科学院上海药物研究所 噻吩并[3,2-d]嘧啶类化合物、其制备方法及用途
EP3645569A4 (fr) 2017-06-26 2021-03-24 BeiGene, Ltd. Immunothérapie pour carcinome hépatocellulaire
US11377449B2 (en) 2017-08-12 2022-07-05 Beigene, Ltd. BTK inhibitors with improved dual selectivity
WO2019108795A1 (fr) 2017-11-29 2019-06-06 Beigene Switzerland Gmbh Traitement de lymphomes à cellules b indolentes ou agressives au moyen d'une combinaison comprenant des inhibiteurs de btk
WO2019208805A1 (fr) * 2018-04-27 2019-10-31 小野薬品工業株式会社 AGENT PRÉVENTIF ET/OU THÉRAPEUTIQUE POUR MALADIE AUTO-IMMUNE COMPRENANT UN COMPOSÉ AYANT UNE ACTIVITÉ INHIBITRICE DE Btk EN TANT QUE PRINCIPE ACTIF
AU2019341284B2 (en) * 2018-09-18 2024-09-05 Beijing Innocare Pharma Tech Co., Ltd. Crystalline forms of 6- (1-acryloylpiperidin-4-yl) -2- (4-phenoxyphenyl) nicotinamide
KR102879159B1 (ko) * 2018-11-06 2025-10-30 베이징 이노케어 파마 테크 씨오., 엘티디. 6-(1-아크릴로일피페리딘-4-일)-2-(4-페녹시페닐)니코틴아미드를 포함하는 무정형 고체 분산액
CN109939223B (zh) * 2019-04-04 2020-04-07 中南大学湘雅二医院 一种白介素2在制备用于治疗寻常型天疱疮口腔糜烂药物的应用
US20220249491A1 (en) 2019-06-10 2022-08-11 Beigene Switzerland Gmbh Oral solid tablet comprising bruton's tyrosine kinase inhibitor and preparation method therefor
KR20220079909A (ko) 2019-10-09 2022-06-14 프린시피아 바이오파마, 인코퍼레이티드 (R)-2-[3-[4-아미노-3-(2-플루오로-4-페녹시-페닐)피라졸로[3,4-d]피리미딘-1-일]피페리딘-1-카르보닐]-4-메틸-4-[4-(옥세탄-3-일)피페라진-1-일]펜트-2-엔니트릴을 투여하여 천포창을 치료하는 방법
US20210106584A1 (en) 2019-10-14 2021-04-15 Principia Biopharma Inc. Methods for treating immune thrombocytopenia by administering (r)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
AU2021205248A1 (en) * 2020-01-08 2022-09-01 Principia Biopharma Inc. Topical pharmaceutical compositions comprising 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4,4-dimethylpent-2-enenitrile
US11814390B2 (en) 2020-01-22 2023-11-14 Principia Biopharma Inc. Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1H-pyrazolo[3,4-D]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
WO2021207662A1 (fr) * 2020-04-10 2021-10-14 Genentech, Inc. Utilisation d'il-22-fc pour le traitement ou la prévention de la pneumonie, du syndrome de détresse respiratoire aiguë ou du syndrome de libération de cytokines
EP4322957A1 (fr) * 2021-04-16 2024-02-21 Principia Biopharma Inc. Procédés de traitement de la thrombocytopénie immunitaire induite par des médicaments et des vaccins par administration de composés spécifiques
US11786531B1 (en) 2022-06-08 2023-10-17 Beigene Switzerland Gmbh Methods of treating B-cell proliferative disorder
KR20250088633A (ko) 2022-10-31 2025-06-17 프린시피아 바이오파마, 인코퍼레이티드 (R)-2-[3-[4-아미노-3-(2-플루오로-4-페녹시-페닐)피라졸로[3,4-d]피리미딘-1-일]피페리딘-1-카르보닐]-4-메틸-4-[4-(옥세탄-3-일)피페라진-1-일]펜트-2-엔니트릴을투여하여 면역 혈소판 감소증을 치료하는 방법
AU2023390489A1 (en) 2022-12-09 2025-07-24 Principia Biopharma Inc. Methods for treating immune thrombocytopenia in subjects with cognitive impairment by administering rilzabrutinib
CN116849178A (zh) * 2023-06-26 2023-10-10 武汉大学中南医院 胎源性成年骨关节炎易感模型的构建方法、共性干预靶标及其应用
WO2025006680A1 (fr) 2023-06-30 2025-01-02 Principia Biopharma Inc. Méthodes de traitement de la thrombocytopénie immunitaire persistante ou chronique chez les enfants, les adolescents et les adultes par administration de (r)-2-[3-[4-amino-3-(2-fluoro-4-phénoxyphényl)pyrazolo[3,4-d]pyrimidin-1-yl]pipéridine-1-carbonyl]-4-méthyl-4-[4-(oxétan-3-yl)pipérazin-1-yl]pent-2-ènenitrile
KR20260040446A (ko) 2023-07-17 2026-03-24 카드몬 코포레이션, 엘엘씨 Btk 저해제 및 벨루모수딜을 포함하는 병용 요법
TW202535404A (zh) 2023-10-25 2025-09-16 美商普林斯匹亞生物製藥公司 使用ｂｔｋ抑制劑２－［（３ｒ）－３－［４－胺基－３－（２－氟－４－苯氧基－苯基）吡唑并［３，４－ｄ］嘧啶－１－基］哌啶－１－羰基］－４－甲基－４－［４－（氧雜環丁烷－３－基）哌𠯤－１－基］戊－２－烯腈治療與異位性皮炎和／或結節性癢疹相關的搔癢
TW202539683A (zh) 2023-12-06 2025-10-16 美商普林斯匹亞生物製藥公司 透過投予（ｒ）－２［３－［４－胺基－３－（２－氟－４－苯氧基－苯基）吡唑並［３，４－ｄ］嘧啶－１－基］哌啶－１－羰基］－４－甲基－４－［４－（氧雜環丁烷－３－基）哌𠯤－１－基］戊－２－烯腈治療中度至重度氣喘
WO2026024765A1 (fr) 2024-07-23 2026-01-29 Principia Biopharma Inc. Traitement de la thrombose veineuse avec du rilzabrutinib et ses dérivés
WO2026024885A1 (fr) 2024-07-24 2026-01-29 Principia Biopharma Inc. Rizalbrutinib pour le traitement de l'anémie hémolytique auto-immune à anticorps chaud
WO2026035812A1 (fr) 2024-08-08 2026-02-12 Principia Biopharma Inc. Méthodes de traitement de la drépanocytose par administration d'un inhibiteur de btk

Family Cites Families (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4082819A (en) 1977-03-02 1978-04-04 The Standard Oil Company Rubber-modified acrylonitrile-vinyl ether-indene polymers
JPS5663950A (en) 1979-10-30 1981-05-30 Mitsubishi Chem Ind Ltd Cyclopropanecarboxylic ester
FR2535721A1 (fr) 1982-11-08 1984-05-11 Sanofi Sa Derives de la piperidinedione protecteurs du myocarde presentant une acticite antiarythmique, leur procede de preparation et les medicaments qui contiennent lesdits derives
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
JPS623848A (ja) 1985-06-28 1987-01-09 Nippon Steel Corp 疲労強度のすぐれたスタツド付きフラツシユバツト溶接アンカ−チエ−ン
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
JP2518353B2 (ja) 1988-06-09 1996-07-24 住友化学工業株式会社 シアノ酢酸アミド誘導体およびその製造中間体
CA2018801C (fr) 1990-06-12 2000-08-22 Pierre Louis Beaulieu Derives peptidiques comprenant une terminaison-n1,4-dioxo-c4
JPH04177244A (ja) 1990-11-10 1992-06-24 Konica Corp ハロゲン化銀写真感光材料
CA2033447C (fr) 1990-12-31 1999-08-31 Robert Deziel Complexe synergique pour le traitement des infections herpetiques
JP2594486B2 (ja) 1991-01-15 1997-03-26 アルコン ラボラトリーズ インコーポレイテッド 局所的眼薬組成物
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
JPH05301838A (ja) 1991-10-15 1993-11-16 Mitsubishi Kasei Corp スチレン誘導体
US5792771A (en) 1992-11-13 1998-08-11 Sugen, Inc. Quinazoline compounds and compositions thereof for the treatment of disease
WO1995024190A2 (fr) 1994-03-07 1995-09-14 Sugen, Inc. Inhibiteurs de tyrosine-kinase receptrice destines a inhiber les troubles lies a la proliferation cellulaire et compositions les contenant
JPH0827090A (ja) 1994-05-13 1996-01-30 Sumitomo Chem Co Ltd シアノ酢酸アミド誘導体、その用途およびその製造中間体
US6331555B1 (en) 1995-06-01 2001-12-18 University Of California Treatment of platelet derived growth factor related disorders such as cancers
DE59808284D1 (de) 1997-03-14 2003-06-12 Basf Ag Cycloalkylalkancarbonsäureamide, deren herstellung und verwendung
US7863444B2 (en) 1997-03-19 2011-01-04 Abbott Laboratories 4-aminopyrrolopyrimidines as kinase inhibitors
IL125947A0 (en) 1997-09-17 1999-04-11 American Cyanamid Co 3-(1,2-benzisothiazol- and isoxazol-5-yl)-2,4(1h,3h)-pyrimidinedione or thione and 3-(1,2-benzisothiazol- and isoxazol-5-yl)-4(3)-pyrimidinone or thione herbicidal agents
JP2001519379A (ja) 1997-10-09 2001-10-23 ペリオ、プロダクツ、リミテッド 遅延性総放出胃腸薬物送達システム
US6713474B2 (en) 1998-09-18 2004-03-30 Abbott Gmbh & Co. Kg Pyrrolopyrimidines as therapeutic agents
EP1169038B9 (fr) 1999-04-15 2013-07-10 Bristol-Myers Squibb Company Inhibiteurs cycliques de proteine tyrosine kinase
JP2003509428A (ja) 1999-09-17 2003-03-11 アボツト・ゲー・エム・ベー・ハー・ウント・コンパニー・カーゲー 治療薬としてのピラゾロピリミジン
AU2000240570A1 (en) 2000-03-29 2001-10-08 Knoll Gesellschaft Mit Beschraenkter Haftung Pyrrolopyrimidines as tyrosine kinase inhibitors
AR042586A1 (es) 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
MXPA03008560A (es) 2001-03-22 2004-06-30 Abbot Gmbh & Co Kg Pirazolopirimidinas como agentes terapeuticos.
CA2465328C (fr) 2001-11-01 2011-06-14 Michael Francis Gross Piperidines
JP3991812B2 (ja) 2001-12-11 2007-10-17 住友化学株式会社 エステル化合物およびその用途
WO2003068157A2 (fr) 2002-02-11 2003-08-21 The Brigham And Women's Hospital, Inc. Inhibiteurs de kinase et leurs procedes d'utilisation
NI200300043A (es) 2002-03-28 2003-11-05 Warner Lambert Co AMINOACIDOS CON AFINIDAD POR LA PROTEINA a2DELTA.
FR2842735B1 (fr) 2002-07-26 2006-01-06 Flamel Tech Sa Microcapsules a liberation modifiee de principes actifs peu solubles pour l'administration per os
GB0219024D0 (en) 2002-08-15 2002-09-25 Pfizer Ltd Synergistic combinations
US7419981B2 (en) 2002-08-15 2008-09-02 Pfizer Inc. Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
GB0226370D0 (en) 2002-11-12 2002-12-18 Novartis Ag Organic compounds
MXPA05008878A (es) 2003-02-21 2005-10-05 Pfizer Derivados de aminotiazol sustituidos con cicloalquilo que contiene n y composiciones farmaceuticas para inhibir la proliferacion celular, y metodos para su uso.
WO2004100868A2 (fr) 2003-04-23 2004-11-25 Abbott Laboratories Procede servant a traiter le rejet d'un transplant
WO2005011812A1 (fr) 2003-08-01 2005-02-10 Chugai Seiyaku Kabushiki Kaisha Composes de cyanoamide utiles en tant qu'inhibiteurs de malonyl-coa decarboxylase
MXPA06002455A (es) 2003-09-02 2006-08-31 Pfizer Prod Inc Formas de dosificacion de liberacion sostenida de ziprasidona.
WO2005023773A1 (fr) 2003-09-04 2005-03-17 Pfizer Limited Procede pour la preparation d'arylpyrazoles substitues
GB0322140D0 (en) 2003-09-22 2003-10-22 Pfizer Ltd Combinations
CA2539976A1 (fr) 2003-09-25 2005-04-07 Warner-Lambert Company Llc Procedes de mise en oeuvre d'acides amines a affinite pour la proteine a2d
JP2007520559A (ja) 2004-02-03 2007-07-26 アボット・ラボラトリーズ 治療薬としてのアミノベンゾオキサゾール類
JP4552456B2 (ja) 2004-02-27 2010-09-29 住友化学株式会社 エステル化合物およびその用途
JPWO2005085210A1 (ja) 2004-03-10 2008-01-17 小野薬品工業株式会社 ニトリル化合物およびその化合物を有効成分として含有する医薬組成物
US7807719B2 (en) 2004-09-14 2010-10-05 Chaim Roifman Compounds useful for modulating abnormal cell proliferation
JP2008514635A (ja) 2004-09-27 2008-05-08 コーザン バイオサイエンシス インコーポレイテッド 特異的キナーゼ阻害剤
AU2006213746A1 (en) 2005-02-11 2006-08-17 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted imidazo(4,5-c) ring compounds and methods
WO2006103661A2 (fr) 2005-03-28 2006-10-05 Dexcel Pharma Technologies Ltd. Absorption regulee de statines dans l'intestin
CA2618646A1 (fr) 2005-06-03 2007-11-15 Xenon Pharmaceuticals Inc. Derives aminothiazole utilises en tant qu'inhibiteurs de la stearoyle-coa desaturase humaine
US7645786B2 (en) 2005-06-15 2010-01-12 Pfizer Inc. Substituted arylpyrazoles
CN101228134A (zh) 2005-06-15 2008-07-23 辉瑞有限公司 用作杀寄生虫剂的取代芳基吡唑
US20080146643A1 (en) 2005-06-15 2008-06-19 Pfizer Limited Combination
US20080176865A1 (en) 2005-06-15 2008-07-24 Pfizer Limited Substituted arylpyrazoles
US20070149464A1 (en) 2005-06-15 2007-06-28 Pfizer Inc. Combination
GB0517205D0 (en) 2005-08-22 2005-09-28 Novartis Ag Organic compounds
JP5222561B2 (ja) 2005-10-07 2013-06-26 キッセイ薬品工業株式会社 含窒素芳香族複素環化合物およびそれを含有する医薬組成物
WO2007064932A2 (fr) 2005-12-02 2007-06-07 Bayer Healthcare Llc. Dérivés de pyrrolotriazine utiles pour traiter le cancer par inhibition de la kinase aurora
KR20080098490A (ko) 2006-01-13 2008-11-10 파마시클릭스, 인코포레이티드 티로신 키나제 억제제 및 이의 용도
RU2456265C2 (ru) 2006-03-31 2012-07-20 Дзе Борд Оф Риджентс Оф Дзе Юниверсити Оф Техас Систем Биологически доступная для перорального применения кофейная кислота, относящаяся к противоопухолевым лекарственным средствам
US7645748B2 (en) 2006-04-03 2010-01-12 Forbes Medi-Tech Inc. Sterol/stanol phosphorylnitroderivatives and use thereof
EP2700638A1 (fr) 2006-05-31 2014-02-26 The Regents Of the University of California Analogues de purine
US20100292229A1 (en) 2006-06-30 2010-11-18 The Board Of Regents Of The University Of Texas System Tryphostin-analogs for the treatment of cell proliferative diseases
ATE523499T1 (de) 2006-07-06 2011-09-15 Array Biopharma Inc Cyclopenta [d]-pyrimidine als akt-proteinkinasehemmer
DK2526933T3 (en) 2006-09-22 2015-05-18 Pharmacyclics Inc Inhibitors of Bruton's tyrosine kinase
CA2668286C (fr) 2006-11-03 2014-09-16 Pharmacyclics, Inc. Sonde d'activite de la tyrosine kinase de bruton et son procede d'utilisation
KR20090086080A (ko) 2006-11-23 2009-08-10 노파르티스 아게 피리미딘 및 그의 ｃｘｃｒ2 수용체 길항제로서의 용도
CN101730699A (zh) 2007-03-21 2010-06-09 百时美施贵宝公司 可用于治疗增殖性、变应性、自身免疫性和炎症性疾病的稠合杂环化合物
GB2447933A (en) 2007-03-27 2008-10-01 Chemence Ltd Cyanoacrylate monomer for forming an adhesive polymer
SG10202107066WA (en) 2007-03-28 2021-07-29 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
JP5368485B2 (ja) 2008-02-25 2013-12-18 エフ．ホフマン−ラ ロシュ アーゲー ピロロピラジンキナーゼインヒビター
CA2712507A1 (fr) 2008-02-25 2009-09-03 F. Hoffmann-La Roche Ag Inhibiteurs de kinase pyrrolopyrazine
KR101324804B1 (ko) 2008-05-13 2013-11-01 아이알엠 엘엘씨 키나제 억제제로서의 질소 함유 융합 헤테로사이클 및 그의 조성물
CA2724715A1 (fr) 2008-05-22 2009-11-26 Amgen Inc. Heterocycles en tant qu'inhibiteurs de proteine kinase
CA2730930C (fr) 2008-07-16 2015-01-13 Pharmacyclics, Inc. Inhibiteurs de tyrosine kinase de bruton pour le traitement de tumeurs solides
JP2011529918A (ja) 2008-08-01 2011-12-15 バイオクライスト ファーマシューティカルズ， インコーポレイテッド Ｊａｋ３阻害剤としてのピペリジン誘導体
US8450337B2 (en) 2008-09-30 2013-05-28 Moleculin, Llc Methods of treating skin disorders with caffeic acid analogs
US20120028981A1 (en) 2008-11-05 2012-02-02 Principia Biopharma Inc. Kinase Knockdown Via Electrophilically Enhanced Inhibitors
US20100113520A1 (en) 2008-11-05 2010-05-06 Principia Biopharma, Inc. Kinase knockdown via electrophilically enhanced inhibitors
US8426428B2 (en) 2008-12-05 2013-04-23 Principia Biopharma, Inc. EGFR kinase knockdown via electrophilically enhanced inhibitors
JP2013504325A (ja) 2009-09-09 2013-02-07 アビラ セラピューティクス， インコーポレイテッド Ｐｉ３キナーゼインヒビターおよびその使用
US7718662B1 (en) 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
US20130035325A1 (en) 2009-11-16 2013-02-07 The Regents Of The University Of California Kinase inhibitors
MX2012013378A (es) 2010-05-20 2013-01-24 Hoffmann La Roche Derivados de pirrolo [2, 3-b] pirazina-7-carboxamida y sus uso como inhibidores de cinasa janus (jak) y cinasa tirosina del brazo (syk).
TWI500617B (zh) 2010-05-31 2015-09-21 Ono Pharmaceutical Co Purine ketone derivatives
CA3007787C (fr) 2010-06-03 2020-03-10 Pharmacyclics Llc Utilisation d'inhibiteurs de la tyrosine kinase de bruton (btk)
US20120071497A1 (en) 2010-06-03 2012-03-22 Pharmacyclics, Inc. Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase
CN101880243A (zh) 2010-06-04 2010-11-10 贵阳柏丝特化工有限公司 一种含氟氰拟除虫菊酯化合物及其合成方法与用途
MX336875B (es) 2010-08-10 2016-02-04 Celgene Avilomics Res Inc Sal de besilato de un inhibidor de tirosina cinasa de bruton (btk).
WO2012158795A1 (fr) 2011-05-17 2012-11-22 Principia Biopharma Inc. Dérivés de pyrazolopyrimidine utilisés comme inhibiteurs de tyrosine kinase
ES2770550T3 (es) 2011-05-17 2020-07-02 Univ California Inhibidores de quinasa
US20140107151A1 (en) 2011-05-17 2014-04-17 Principia Biophama Inc. Tyrosine kinase inhibitors
PL2710005T3 (pl) 2011-05-17 2017-07-31 Principia Biopharma Inc. Inhibitory kinazy tyrozynowej
US8828426B2 (en) 2011-06-07 2014-09-09 Zx Pharma, Llc Multiparticulate L-carnitine compositions and related methods
MX2014000130A (es) 2011-06-28 2014-05-01 Pharmacyclics Inc Procedimientos y composiciones para la inhibicion de resorcion osea.
JP2014520863A (ja) 2011-07-13 2014-08-25 ファーマサイクリックス，インク． Ｂｒｕｔｏｎ型チロシンキナーゼの阻害剤
EP3689878B1 (fr) * 2011-07-19 2021-10-06 Merck Sharp & Dohme B.V. 4-imidazopyridazin-1-yl-benzamides et 4-imidazotriazin-1-yl-benzamides en tant qu'inhibiteurs btk
EP2548877A1 (fr) 2011-07-19 2013-01-23 MSD Oss B.V. Dérivés de 4-(pyridine condensée à 5 chaînons)benzamide comme inhibiteurs de BTK
CA2841887A1 (fr) 2011-07-19 2013-01-24 Merck Sharp & Dohme B.V. 4-imidazopyridazin-1-yl-benzamides et 4-imidazotriazin-1-yl-benzamides inhibiteurs de btk
CN103874699A (zh) 2011-09-20 2014-06-18 赛尔佐姆有限公司 吡唑并[4,3-c]吡啶衍生物作为激酶抑制剂
MX391121B (es) 2011-10-19 2025-03-19 Pharmacyclics Llc Uso de inhibidores de la tirosina cinasa de bruton (btk).
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
US8501724B1 (en) 2012-01-31 2013-08-06 Pharmacyclics, Inc. Purinone compounds as kinase inhibitors
US9353087B2 (en) * 2012-06-08 2016-05-31 Biogen Ma Inc. Inhibitors of Bruton's tyrosine kinase
WO2013191965A1 (fr) * 2012-06-18 2013-12-27 Principia Biopharma Inc. Pyrrolopyrimidines ou pyrazolopyrimidines covalentes réversibles utiles pour le traitement du cancer et de maladies auto-immunes
US20150140085A1 (en) 2012-06-29 2015-05-21 Principia Biopharma Inc. Formulations comprising ibrutinib
WO2014022569A1 (fr) 2012-08-03 2014-02-06 Principia Biopharma Inc. Traitement de la sécheresse oculaire
SI2892900T1 (en) 2012-09-10 2018-01-31 Principia Biopharma Inc. Pyrazolopyrimidine compounds as kinase inhibitors
KR101668574B1 (ko) 2012-11-02 2016-10-24 화이자 인코포레이티드 브루톤 티로신 키나제 억제제
EA201590855A1 (ru) 2012-11-15 2015-11-30 Фармасайкликс, Инк. Соединения пирролопиримидина как ингибиторы киназ
US20140142099A1 (en) 2012-11-20 2014-05-22 Principia Biopharma Inc. Purinone Derivatives as Tyrosine Kinase Inhibitors
JO3377B1 (ar) * 2013-03-11 2019-03-13 Takeda Pharmaceuticals Co مشتقات بيريدينيل وبيريدينيل مندمج
US8957080B2 (en) 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
WO2015132799A2 (fr) 2014-02-03 2015-09-11 Cadila Healthcare Limited Nouveaux composés hétérocycliques
CN112353806A (zh) 2014-02-21 2021-02-12 普林斯匹亚生物制药公司 Btk抑制剂的盐和固体形式
SG11201704808VA (en) 2014-12-18 2017-07-28 Principia Biopharma Inc Treatment of pemphigus
US20180193274A1 (en) 2014-12-24 2018-07-12 Principia Biopharma Inc. Compositions for ileo-jejunal drug delivery
PT3236953T (pt) 2014-12-24 2021-01-29 Principia Biopharma Inc Dosagem específica de sítio de um inibidor de btk
UA124090C2 (uk) 2015-06-03 2021-07-21 Прінсіпіа Байофарма Інк. Інгібітори тирозинкінази
WO2016210165A1 (fr) 2015-06-24 2016-12-29 Principia Biopharma Inc. Inhibiteurs de la tyrosine kinase
CN105753863B (zh) 2015-09-11 2018-07-31 东莞市真兴贝特医药技术有限公司 氧代二氢咪唑并吡啶类化合物及其应用
EP3414234B1 (fr) 2015-10-14 2022-06-29 Zibo Biopolar Changsheng Pharmaceutical Co. Ltd. Inhibiteurs de la tyrosine kinase de bruton
CN115054586B (zh) 2016-06-29 2024-08-02 普林斯匹亚生物制药公司 改性的释放制剂

Also Published As

Publication number Publication date
CN107257686B (zh) 2021-01-29
IL252839A0 (en) 2017-08-31
ES2843323T3 (es) 2021-07-16
EA201791243A1 (ru) 2017-12-29
AU2015364335B2 (en) 2020-11-26
BR112017013022A2 (pt) 2018-02-27
AU2015364335A1 (en) 2017-07-20
PL3233103T3 (pl) 2021-04-19
US10485797B2 (en) 2019-11-26
EA036269B1 (ru) 2020-10-21
MX2017007973A (es) 2018-02-09
CA2970723A1 (fr) 2016-06-23
EP3233103A1 (fr) 2017-10-25
SG11201704808VA (en) 2017-07-28
CA2970723C (fr) 2023-09-05
US20180050027A1 (en) 2018-02-22
EP3233103B1 (fr) 2020-10-14
AU2020264338A1 (en) 2020-12-03
US10946008B2 (en) 2021-03-16
IL252839B (en) 2021-03-25
PT3233103T (pt) 2021-01-18
MX381283B (es) 2025-03-12
US20200101059A1 (en) 2020-04-02
WO2016100914A1 (fr) 2016-06-23
CN107257686A (zh) 2017-10-17

Similar Documents

Publication Publication Date Title
MA41197B1 (fr) Traitement de le pemphigus
CY1110435T1 (el) Μεθοδοι και συνθεσεις για τη θεραπεια οφθαλμικων καταστασεων με παραγωγα ρετινολης
PH12020551425A1 (en) Rimegepant for cgrp related disorders
MA40768B1 (fr) Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue
PH12017500927A1 (en) Envenomation therapies and related pharmaceutical compositions, systems and kits
MA38961A1 (fr) Composés 3-phenyl-1h-pyrazolo[3,4-d]pyrimidin-4-ylamine substitués inhibiteurs de la tyrosine kinase de bruton utilisés pour traiter par exemple les maladies auto-immunes, respiratoires et inflammatoires, cancer, mastocytose et osteoporose
EP3708168A3 (fr) Combinaisons comprenant du dextrométhorphane deutéré et de la quinidine destinées au traitement de l'agitation dans le cadre d'une démence
MX2019007586A (es) Composiciones que comprenden tacrolimus para el tratamiento de enfermedades inflamatorias intraoculares.
EP4335418A3 (fr) Compositions et méthodes pour le traitement du ptérygion
EP4610279A3 (fr) Compositions et procédés d'inhibition de masp-3 pour le traitement de maladies et troubles divers
TW201613919A (en) Inhibitors of Bruton's tyrosine kinase
JO3776B1 (ar) التركيبات الصيدلانية لمثبط CDK4 / 6 ومثبط B-Raf
MX2017015574A (es) Inhibidores de tirosina quinasa de bruton.
MX2017010982A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
MA41238A (fr) Dérivés 5-[(pipérazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione en tant qu'inhibiteurs d'adamts pour le traitement de l'ostéoarthrit
MA46366B1 (fr) Procédé sûr et efficace de traitement du psoriasis avec un anticorps spécifique contre l'il-23
AU2012286851A8 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
MA38827A1 (fr) Combinaison d'un inhibiteur de mek et d'un inhibiteur d'erk pour l'utilisation dans le traitement de maladies hyperprolifératives
NZ792518A (en) Formulations for administration of eflornithine
WO2015095834A3 (fr) Traitements du cancer faisant appel à des inhibiteurs des familles erk1/2 et bcl-2
MX2022000712A (es) Moduladores de nlrp3.
EA201791225A1 (ru) Композиции и способы применения солабегрона с модифицированным высвобождением при симптомах нижних мочевых путей
EP4286013A3 (fr) Inhibiteurs de lrrc33 et utilisations de ceux-ci
PH12022550843A1 (en) Thienopyrimidones as trpa1 inhibitors
EA201171035A1 (ru) Композиции, включающие модуляторы pde4, и способ их применения для лечения, профилактики и сопровождения туберкулеза